# LEGEND-T2DM Evidence Dissemination Summary

Target: **sitagliptin**, Comparator: **dapagliflozin** Outcome: **Bladder cancer** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	46,431	38,540	24	0.62
Clinformatics	25,134	19,918	29	1.46
DA Germany	17,474	18,447	13	0.70
LDP France	-	-	-	-
MDCD	6,866	4,768	<5	<1.05
MDCR	7,457	6,085	14	2.30
Open Claims	621,298	552,075	503	0.91
Optum EHR	56,849	27,238	29	1.06
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)